EA199801044A1 - Модуляторы регенерации тканей - Google Patents

Модуляторы регенерации тканей

Info

Publication number
EA199801044A1
EA199801044A1 EA199801044A EA199801044A EA199801044A1 EA 199801044 A1 EA199801044 A1 EA 199801044A1 EA 199801044 A EA199801044 A EA 199801044A EA 199801044 A EA199801044 A EA 199801044A EA 199801044 A1 EA199801044 A1 EA 199801044A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
tissue regeneration
proteins
stimulated
damaged
Prior art date
Application number
EA199801044A
Other languages
English (en)
Other versions
EA004402B1 (ru
Inventor
Мишель Саникола-Надель
Джозеф В. Бонвентре
Катрин Хессион
Такахару Итимура
Генри Вей
Ричард Л. Кейт
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199801044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA199801044A1 publication Critical patent/EA199801044A1/ru
Publication of EA004402B1 publication Critical patent/EA004402B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Описаны белки, которые стимулируются в поврежденных или регенерирующих тканях, и ДНК, кодирующая эти белки, а также терапевтические композиции и способы лечения с использованием этих соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199801044A 1996-05-24 1997-05-23 Модуляторы регенерации тканей EA004402B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (2)

Publication Number Publication Date
EA199801044A1 true EA199801044A1 (ru) 1999-04-29
EA004402B1 EA004402B1 (ru) 2004-04-29

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199801044A EA004402B1 (ru) 1996-05-24 1997-05-23 Модуляторы регенерации тканей

Country Status (27)

Country Link
US (4) US6664385B1 (ru)
EP (2) EP0907735B9 (ru)
JP (3) JP4602482B2 (ru)
CN (1) CN1147584C (ru)
AT (1) ATE318903T1 (ru)
AU (1) AU712289B2 (ru)
BG (1) BG64678B1 (ru)
BR (1) BR9709115A (ru)
CA (1) CA2257851C (ru)
CZ (1) CZ295936B6 (ru)
DE (1) DE69735364T3 (ru)
DK (1) DK0907735T5 (ru)
EA (1) EA004402B1 (ru)
EE (1) EE04817B1 (ru)
ES (1) ES2258793T5 (ru)
HK (1) HK1021746A1 (ru)
HU (1) HU226205B1 (ru)
IL (1) IL127162A (ru)
IS (1) IS2636B (ru)
NO (2) NO327597B1 (ru)
NZ (1) NZ336467A (ru)
PL (1) PL188826B1 (ru)
PT (1) PT907735E (ru)
SI (1) SI0907735T2 (ru)
SK (1) SK285461B6 (ru)
TR (1) TR199802421T2 (ru)
WO (1) WO1997044460A1 (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK285461B6 (sk) * 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
AU7592998A (en) * 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration
SK287538B6 (sk) 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (en) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
AU6986201A (en) * 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DE60224275T2 (de) * 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
WO2003002722A2 (en) 2001-06-29 2003-01-09 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2311122T3 (es) 2002-12-30 2009-02-01 Biogen Idec Ma Inc. Antagonistas de kim-1 y uso para la modulacion del sistema inmune.
AU2004224390A1 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
ES2754753T3 (es) * 2003-03-27 2020-04-20 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
JP2007536260A (ja) 2004-05-06 2007-12-13 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 虚血性および腎毒性障害の軽減および改善用ｎｇａｌ
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
JP4741603B2 (ja) * 2004-12-20 2011-08-03 アンチボディショップ・アクティーゼルスカブ 腎障害の診断用マーカーとしての好中球ゼラチナーゼ関連リポカリン（ｎｇａｌ）の測定
DE602006016413D1 (de) 2005-03-02 2010-10-07 Biogen Idec Inc Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
JP2009515897A (ja) 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
EP2035835B1 (en) 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
EP2602624A1 (en) * 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
NZ610356A (en) * 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104399089B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX2011007810A (es) * 2009-01-28 2011-09-30 Ind Tech Res Inst Biomarcadores asociados con nefropatia.
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279302B2 (en) * 2009-08-07 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011057147A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
JP2013519095A (ja) 2010-02-05 2013-05-23 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
KR20140051754A (ko) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ703055A (en) 2010-06-23 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2672980B1 (en) * 2011-02-09 2017-12-06 Lavivo AB Synbiotic compositions for restoration and reconstitution of gut microbiota
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
AU2014207509B2 (en) 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
US10265424B2 (en) * 2014-03-04 2019-04-23 Trust-Biosonics, Inc. Molecular imaging contrast agents and uses thereof
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2166313A1 (en) * 1994-02-14 1995-08-17 John N. Simons Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
WO1996006159A1 (en) * 1994-08-18 1996-02-29 The Trustees Of Columbia University In The City Of New York Unique associated kaposi's sarcoma virus sequences and uses thereof
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
SK285461B6 (sk) * 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
AU6986201A (en) * 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
DE60224275T2 (de) * 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
WO2003002722A2 (en) * 2001-06-29 2003-01-09 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2311122T3 (es) * 2002-12-30 2009-02-01 Biogen Idec Ma Inc. Antagonistas de kim-1 y uso para la modulacion del sistema inmune.
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005097211A2 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use

Also Published As

Publication number Publication date
EP0907735B2 (en) 2009-10-07
CA2257851C (en) 2011-11-15
ES2258793T3 (es) 2006-09-01
SI0907735T1 (sl) 2006-08-31
CZ295936B6 (cs) 2005-12-14
PT907735E (pt) 2006-06-30
BR9709115A (pt) 1999-08-03
CZ381398A3 (cs) 1999-05-12
EE04817B1 (et) 2007-04-16
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
CA2257851A1 (en) 1997-11-27
HK1021746A1 (en) 2000-06-30
AU712289B2 (en) 1999-11-04
NO985427L (no) 1999-01-25
NZ336467A (en) 2000-10-27
US20050089868A1 (en) 2005-04-28
US6664385B1 (en) 2003-12-16
JP2008067701A (ja) 2008-03-27
IS4902A (is) 1998-11-20
AU3567697A (en) 1997-12-09
NO985427D0 (no) 1998-11-20
IL127162A0 (en) 1999-09-22
BG64678B1 (bg) 2005-11-30
NO327597B1 (no) 2009-08-31
CN1223685A (zh) 1999-07-21
NO20090945L (no) 1999-01-25
DK0907735T3 (da) 2006-06-26
SI0907735T2 (sl) 2010-01-29
EP0907735A1 (en) 1999-04-14
CN1147584C (zh) 2004-04-28
WO1997044460A1 (en) 1997-11-27
US20060286031A1 (en) 2006-12-21
JP4602482B2 (ja) 2010-12-22
ES2258793T5 (es) 2010-01-25
EP0907735B1 (en) 2006-03-01
PL330313A1 (en) 1999-05-10
IS2636B (is) 2010-06-15
DE69735364T2 (de) 2006-11-30
DK0907735T4 (da) 2009-12-21
DK0907735T5 (da) 2010-06-14
DE69735364T3 (de) 2010-05-06
DE69735364D1 (de) 2006-04-27
IL127162A (en) 2007-07-24
PL188826B1 (pl) 2005-04-29
EP1655367A1 (en) 2006-05-10
JP2009039111A (ja) 2009-02-26
BG102967A (bg) 2000-05-31
EA004402B1 (ru) 2004-04-29
EP0907735B9 (en) 2010-05-19
HUP9902770A2 (hu) 1999-12-28
SK285461B6 (sk) 2007-02-01
HU226205B1 (en) 2008-06-30
SK160998A3 (en) 1999-07-12
ATE318903T1 (de) 2006-03-15
EE9800409A (et) 1999-06-15
US20070141590A1 (en) 2007-06-21
JP4316640B2 (ja) 2009-08-19
TR199802421T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
EA199801044A1 (ru) Модуляторы регенерации тканей
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
EA199800667A1 (ru) Новые фенантридины
FI844510L (fi) Ensym-resistenta immunsystemet modulerande peptider.
EA199800946A1 (ru) Концентрированный препарат антител
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
ATE232399T1 (de) Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ITBO930059A1 (it) Procedimento per ottenere la rigenerazione dei tessuti nella terapia odontoiatrica parodentale.
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
EA200100785A1 (ru) Шипучие слабительные средства
EA200100385A1 (ru) Композиция и способ лечения нарушения гемостаза у субъекта (варианты)
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU